spacer
home > ict > spring 2008 > materialising markets
PUBLICATIONS
International Clinical Trials

Materialising Markets

Jerry Boxall of ACM-Pivotal Europe explores the pros and cons of clinical research in the emerging markets from the point of view of a global clinical trials organisation

As the global market continues to expand, pharmaceutical companies must make decisions about which of the key emerging regions to focus on when it comes to clinical trials. Expansion into new markets is nothing new for the pharmaceutical industry, and within Europe we have seen the countries of Central and Eastern Europe (CEE) emerge as major centres for clinical research over the past decade. As with every new opportunity, there are risks associated with conducting research in emerging regions, and a look back at the lessons learnt from the CEE region may be a valuable exercise in identifying potential threats in new locations across the globe.

There is no doubt that momentum is gathering in favour of the emerging economies. According to the Financial Times, the proportion of principal investigators registered with the US Food and Drug Administration – but based outside the US and Western Europe – rose from five per cent in 1997 to 29 per cent last year, with the fastest growth coming from India, China, Russia and Argentina in the past five years (1). These regions are prime clinical trial locations; they offer low cost services, skilled investigators, and a large, diverse pool of highly compliant patients.

Companies that have already explored the opportunities in these new locations have increased patient recruitment by 20 to 30 per cent, whilst also reducing costs. In Phase III trials, research shows that it is common for results to come in six or seven months quicker than in domestic markets – all elements that help to get the drug to market and generate revenue more quickly. However, the globalisation of clinical trials has faced increasing scrutiny over issues such as the quality of data, ethical considerations and the safety of the patients involved.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jerry Boxall is a Member of the Institute of Clinical Research (ICR) and is Managing Director, Europe, of ACM-Pivotal. Trained as a Biomedical Scientist, Jerry has over 25 years’ experience in this field. For the past 15 years he has held senior central laboratory posts both in the UK and Europe. Jerry has been heavily involved in the establishment of both European and global central laboratories in Germany, France, Denmark, the Netherlands and the UK. Jerry joined the ACM-Pivotal team from CRL-Medinet in June 2000 as Head of European Operations, and took over as Managing Director, Europe, in January 2005
spacer
Jerry Boxall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers
 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement